In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sonia Lwoff, director, clinical operations, Rho, discusses the potential for artificial intelligence in clinical trial decision-making and enrollment.
ACT: Is there any potential for the use of AI when it comes to decision-making and enrollment?
Lwoff: In the trial development process, AI algorithms can analyze existing data to predict trial outcomes and identify optimal trial designs. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. Some site networks are already working with AI to check on their medical records to identify patients. However, we need to be mindful of how this data is being used at hospitals. There are some data privacy considerations. AI can process also and analyze data in real time and detect anomalies and potential issues more quickly than the traditional methods. Last but not least, AI may also be used to analyze previous trials data to start using it for site selection and to predict which sites may perform optimally in a given trial based on the previous experience with those sites.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.